课题基金 / 基金详情

Immune signatures of vaccine responses in vulnerable populations

Immune signatures of vaccine responses in vulnerable populations
弱势群体疫苗反应的免疫特征
批准号:
10420322
负责人:
David A. Hafler
金额:
$287.43万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
未结题
起止时间:
2010-07-12 至 2027-04-30

项目摘要

项目成果

David A. Hafler的其他基金

相似基金

相关文献

中文摘要
翻译
摘要
英文摘要
ABSTRACT We propose a deep interrogation and a systems approach that will identify molecular signatures to vaccination across three cohorts of vulnerable patient populations: autoimmune patients with B cell depletion, aged and frail individuals, and patients with sickle cell disease who are functionally asplenic. These distinct populations share a dysregulated inflammatory milieu that is linked to poor vaccination responsiveness. We have assembled an interdisciplinary team of investigators with a track record of longstanding and productive collaborations to use a systems approach that combines well-defined and understudied cohorts with unbiased large-scale profiling to elucidate signatures defining vaccine responsiveness. This goal will be accomplished by: 1) examining three vulnerable patient cohorts challenged with different vaccines, including novel mRNA vaccines and one shared vaccine; 2) using shared platforms that deeply interrogate immune responses from blood and limited-access compartments; and 3) refining new mathematical tools for multidimensional analysis of data to identify active pathways and modules and to determine specific connections among components in the immune network that contribute to differential vaccine effectiveness. This effort capitalizes on recent advances in single- cell and spatial immune profiling methods along with shared immunologic and proteomic platforms to create a novel public resource for vulnerable populations that characterizes diverse states of the human immune system. Integration across our cohorts will support the development of molecular signatures of vaccination responses and identify critical pathways relevant for potential therapeutic strategies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122
  • 批准号:
    10346649
  • 项目类别:
  • 资助金额:
    $69.51万
  • 财政年份:
    2022
  • 负责人:
    David A. Hafler
  • 依托单位:
Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122
  • 批准号:
    10573141
  • 项目类别:
  • 资助金额:
    $67.34万
  • 财政年份:
    2022
  • 负责人:
    David A. Hafler
  • 依托单位:
Systems Immune Profiling of Divergent Responses to Infection
  • 批准号:
    10265709
  • 项目类别:
  • 资助金额:
    $107.73万
  • 财政年份:
    2020
  • 负责人:
    David A. Hafler
  • 依托单位:
Systems Immune Profiling of Divergent Responses to Infection
  • 批准号:
    10205567
  • 项目类别:
  • 资助金额:
    $45.42万
  • 财政年份:
    2020
  • 负责人:
    David A. Hafler
  • 依托单位:
海外基金